In an American Arbitration Association (AAA) dispute over early-stage drug candidates in a development agreement between two pharmaceutical companies, CRA consultants were retained to assist in expert reports regarding industry practices regarding exclusivity of drug product candidates. A key issue was whether exclusivity was limited to individual antibodies and who had the right to select the antibodies for development. The reports addressed the scope and breadth of exclusivity in the industry and whether the payments in the contract were consistent with broad or narrow exclusivity.
World Orphan Drug Congress Europe 2024 Review: 3 Themes for sustainable and equitable access to medicines for RD patients
This year’s European World Orphan Drug Congress, attended by CRA’s Bhavesh Patel, Michele Pistollato, Charlotte Poon, Owen Male and Clara Zacharko in...